

Financial Tear Sheet

Corporate Profile

Bioverativ is a global biopharmaceutical company dedicated to transforming the lives of people with hemophilia and other rare blood disorders through world-class research, development and commercialization of innovative therapies. Launched in 2017 following separation from Biogen Inc., Bioverativ builds upon a strong heritage of scientific innovation and is committed to actively working with the blood disorders community. The company's mission is to create progress for patients where they need it most, and its hemophilia therapies, when launched, represented the first major advancements in hemophilia treatment in more than two decades. For more information, visit www.bioverativ.com or follow @Bioverativ on Twitter.

Primary IR Contact

Investor Relations
Phone: 781-663-4360
E-mail: IR@bioverativ.com

Stock Information

BIVV (Common Stock)

Exchange	NASDAQ GS (US Dollar)
Price	\$103.91
Change (%)	▲ 0.10 (0.10%)
Volume	1,267,038
52 Week Low	\$46.75
Market Cap	\$11,245,518,848
Rolling EPS	2.74
PE Ratio	37.9529
Shares Outstanding	108,223,644

Data as of 02/21/18 4:00 p.m. ET

Data provided by Nasdaq. Minimum 15 minutes delayed.



Recent News & Upcoming Events

02/14/18
 Haemophilia Publishes a Retrospective Analysis Investigating the Use of ELOCTATE® for Immune Tolerance Induction in People with Inhibitors and Severe Hemophilia A

02/13/18
 Bioverativ Reports Fourth Quarter and Full Year 2017 Performance

01/22/18
 Sanofi to Acquire Bioverativ for \$11.6 Billion

There are currently no events scheduled.

SEC Filings

Filing Date	Form
02/20/18	SC TO-T/A
02/20/18	SC 14D9/A
02/15/18	4
02/15/18	4